SG Americas Securities LLC has increased its stock position in
Edwards Lifesciences Corporation (EW), while there are reports of
Vanguard affiliate having zero holdings in the company. Despite some pullbacks in pricing, there's speculation whether it presents a buying opportunity. Analysts expect further developments from EW's upcoming Quarterly Earnings Report.
Assenagon Asset Management S.A and
Bank of Montreal have acquired more $EW shares, and EW stock demonstrates potential to outperform even the S&P 500. Meanwhile, EW's shares continue their popularity among institutional investors, holding 88%. The company’s
valuation has been the focus post recent price momentum with some predicting the stock could reach $150. However, $EW's recent share price swings seem to stretch pricing, despite optimistic views about its renewed growth cycle. Notably, records show officer transactions with substantial share sales. Severe insider provisions, including sales, exerting pressure on stock. Expectations for EW’s Q4 2025 earnings report remain high, possibly affecting its long-term narrative and growth projection. Finally, the Street has a ‘Moderate Buy’ consensus on this stock after a reported 14% gain last year. However, stock slid 3.3% as investors digested recent conference remarks and filings about share sales.
Edwards Lifesciences Corp EW News Analytics from Fri, 25 Jul 2025 07:00:00 GMT to Fri, 27 Mar 2026 22:14:29 GMT -
Rating 5
- Innovation 3
- Information 9
- Rumor -4
